The Anglo-Swedish drugmaker has previously admitted in court documents that the vaccine causes side effects such as blood clots and low blood platelet counts.
This development led to sharp criticism from the Africa Centres for Disease Control and Prevention (Africa CDC), which accused Moderna of "abandoning a commitment to build highly needed and relevant vaccine manufacturing capabilities in Africa."
Moderna disclosed that it hasn't received any vaccine orders for Africa since 2022, further revealing the cancellation of previous orders.
Surveillance data from the lake region indicates a rise in positive samples of SARS-CoV-2, identifying both the JN.1 variant of Omicron and the H1N1 influenza strain.
Kenya's call aligns with efforts to bolster healthcare infrastructure and reduce dependency on external vaccine sources, as was the case during the COVID-19 pandemic.